Multi-center, Double-blind, Parallel-group, Randomized, Placebo-controlled, Three Doses, 40-week Extension to Studies ID-078A301 and ID-078A302 to Assess the Long Term Safety and Tolerability of ACT-541468 in Adult and Elderly Subjects With Insomnia Disorder
Phase of Trial: Phase III
Latest Information Update: 05 Dec 2019
Price : $35 *
At a glance
- Drugs Daridorexant (Primary)
- Indications Insomnia
- Focus Adverse reactions; Registrational
- Sponsors Idorsia Pharmaceuticals
- 05 Dec 2019 According to an Idorsia Pharmaceuticals media release, data from this trial is expected in mid-2020.
- 15 Oct 2019 Planned End Date changed from 16 Sep 2020 to 6 Mar 2021.
- 15 Oct 2019 Planned primary completion date changed from 1 Jul 2020 to 25 Feb 2021.